Article information
Full text is only aviable in PDF
REFERENCES
[1]
GE D'Alonzo, RJ Barst, SM Ayres, EH Bergofsky, BH Brundage, KM Detre, et al.
Survival in patients with primary pulmonary hypertension: results from a national prospective registry.
Ann Intern Med, 115 (1991), pp. 343-349
[2]
S Rich, E Kaufmann, PS Levy.
The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension.
N Engl J Med, 327 (1992), pp. 76-81
[3]
A Chapelier, P Vouhé, P Macchiarini, B Lenot, J Cerrina, F le Roy Ladurie, et al.
Comparative outcome of heart-lung and lung transplantation for pulmonary hypertension.
J Thorac Cardiovasc Surg, 106 (1993), pp. 299-307
[4]
S Moncada, R Gryglewski, S Bunting, JR Vane.
An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation.
Nature, 263 (1976), pp. 663-665
[5]
LJ Rubin, J Mendoza, M Hood, MD McGoon, R Barst, WB Willians, et al.
Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol): results of a randomized trial.
Ann Intern Med, 112 (1990), pp. 485-491
[6]
RJ Barst, LJ Rubin, WA Long, MD McGoon, S Rich, DB Badesch, et al.
A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group.
N Engl J Med, 334 (1996), pp. 296-302
[7]
VV McLaughlin, A Shillington, S Rich.
Survival in primary pulmonary hypertension: the impact of epoprostenol therapy.
Circulation, 106 (2002), pp. 1477-1482
[8]
N Galie, A Manes, A Branzi.
Medical therapy of pulmonary hypertension, the prostacyclins.
Clin Chest Med, 22 (2001), pp. 529-537
[9]
H Olchewsky, D Walmrath, R Schermuly, A Ghofrani, F Grimminger, W Seeger.
Aerosolized prostacyclin and iloprost in severe pulmonary hypertension.
Ann Intern Med, 124 (1996), pp. 820-824
[10]
H Olchewsky, HA Ghofrani, T Schmehl, J Winkler, H Wilkens, MM Höper, et al.
Inhaled iloprost to treat severe pulmonary hypertension. An uncontrolled trial.
Ann Intern Med, 132 (2000), pp. 435-443
[11]
MM Hoeper, M Schwarze, S Ehlerding, A Adler-Schuermeyer, E Spiekerkoetter, J Niedemeyer, et al.
Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue.
N Engl J Med, 342 (2000), pp. 1866-1870
[12]
H Olschewski, G Simonneau, N Galie, T Higenbottam, R Naeije, LJ Rubin, et al.
Inhaled iloprost for severe pulmonary hypertension.
N Engl J Med, 347 (2002), pp. 322-329
[13]
G Simonneau, RJ Barst, N Galie, R Naeije, S Rich, RC Bourge, et al.
Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension.
Am J Respir Crit Care Med, 165 (2002), pp. 800-804
[14]
I Lang, M Gómez-Sánchez, M Kneussl, R Naeije, P Escribano, N Skoro-Sajer, et al.
Efficacy of long term subcutaneous treprostinil sodium therapy in pulmonary hypertension.
Chest, 129 (2006), pp. 1636-1643
[15]
RJ Barst, M McGoon, V McLaughlin, VF Tapson, S Rich, LJ Rubin, et al.
Beraprost therapy for pulmonary arterial hypertension.
J Am Coll Cardiol, 41 (2003), pp. 2119-2125
[16]
M Yanagisawa, H Kurihara, S Kimura, Y Tomobe, M Kobayashi, Y Mitsui, et al.
A novel potent vasoconstrictor peptide produced by vascular endothelial cells.
Nature, 332 (1998), pp. 411-415
[17]
D Stewart, RD Levy, P Cernacek, D Langleben.
Increased plasma endothelin-1 in pulmonary hypertension: marker or mediator of disease?.
Ann Intern Med, 114 (1991), pp. 464-469
[18]
RN Channick, G Simonneau, O Sitbon, IM Robbins, A Frost, VF Tapson, et al.
Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study.
Lancet, 358 (2001), pp. 1119-1123
[19]
LJ Rubin, DB Badesch, RJ Barst, N Galie, CM Black, A Keogh, et al.
Bosentan therapy for pulmonary arterial hypertension.
N Engl J Med, 346 (2002), pp. 896-903
[20]
V McLaughlin, O Sitbon, DB Badesch, RJ Barst, C Black, N Galie, et al.
Survival with first-line bosentan in patients with primary pulmonary hypertension.
Eur Respir J, 25 (2005), pp. 244-249
[21]
N Galie, D Badesch, R Oudiz, G Simonneau, MD McGoon, AM Keogh, et al.
Ambrisentan therapy for pulmonary arterial hypertension.
J Am Coll Cardiol, 46 (2005), pp. 529-535
[22]
N Galie, HA Ghofrani, A Torbicki, RJ Barst, LJ Rubin, D Badesch, et al.
Sildenafil citrate therapy for pulmonary arterial hypertension.
N Engl J Med, 353 (2005), pp. 2148-2157
[23]
JC Caraballo, CD Martínez, R Sánchez de León.
Disfunción endotelial en la hipertensión pulmonar.
Arch Bronconeumol, 41 (2005), pp. 389-392
[24]
DB Badesch, SH Abman, GS Ahearn, RJ Barst, DC MCCrory, G Simonneau, et al.
Medical therapy for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines.
Chest, 126 (2004), pp. 35-62
[25]
N Galie, W Seeger, R Naeije, G Simonneau, LJ Rubin.
Comparative analysis of clinical trials and evidence-based treatment algorithm in pulmonary arterial hypertension.
J Am Coll Cardiol, 43 (2004), pp. 81-88
[26]
N Galie, A Torbicki, RJ Barst, P Dartevelle, S Haworth, T Higenbottam, et al.
Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology.
Eur Heart J, 25 (2004), pp. 2243-2278
[27]
R Wensel, CF Opitz, SD Anker, J Winkler, G Hoffken, FX Kleber, et al.
Assessment of survival in patients with primary pulmonary hypertension: importance of cardiopulmonary exercise testing.
Circulation, 106 (2002), pp. 319-324
[28]
O Sitbon, M Humbert, H Nunes, F Parent, G García, P Herve, et al.
Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival.
J Am Coll Cardiol, 40 (2002), pp. 780-788
[29]
MM Hoeper, C Faulenbach, H Golpon, J Winkler, T Welte, J Niedermeyer.
Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension.
Eur Respir J, 24 (2004), pp. 1007-1010
[30]
GA Paul, JS Gibbs, AR Boobis, A Abbas, MR Wilkins.
Bosentan decreases the plasma concentration of sildenafil when coprescribed in pulmonary hypertension.
Br J Clin Pharmacol, 60 (2005), pp. 107-112
[31]
HJ Seyfarth, H Pankau, S Hammerschmidt, J Schauer, H Wirtz, J Winkler.
Bosentan improves exercise tolerance and Tei index in patients with pulmonary hypertension and prostanoid therapy.
Chest, 128 (2005), pp. 709-713
[32]
M Humbert, RJ Barst, IM Robbins, RN Channick, N Galie, A Boonstra, et al.
Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2.
Eur Respir J, 24 (2004), pp. 353-359
[33]
MM Hoeper, I Markevych, E Spiekerkoetter, T Welte, J Niedermeyer.
Goal-oriented treatment and combination therapy for pulmonary arterial hypertension.
Eur Respir J, 26 (2005), pp. 858-863
[34]
V Pengo, A Lensing, MH Prins, A Marchiori, BL Davidson, F Tiozzo, et al.
Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism.
N Engl J Med, 50 (2004), pp. 2257-2264
[35]
PF Fedullo, WR Auger, KM Kerr, LJ Rubin.
Chronic thromboembolic pulmonary hypertension.
N Engl J Med, 345 (2001), pp. 1465-1472
[36]
MM Hoeper, T Kramm, H Wilkens, C Schulze, HJ Schafers, T Welte, et al.
Bosentan therapy for inoperable chronic thromboembolic pulmonary hypertension.
Chest, 128 (2005), pp. 2363-2367
[37]
RJ Hughes, X Jais, D Bonderman, J Suntharalingam, M Humbert, I Lang, et al.
The efficacy of bosentan in inoperable chronic thromboembolic hypertension: a 1-year follow-up study.
Eur Respir J, 28 (2006), pp. 138-143
[38]
MM Hoeper, M Halank, C Marx, G Hoeffken, HJ Seyfarth, J Schauer, et al.
Bosentan for porto-pulmonary hypertension.
Eur Respir J, 25 (2005), pp. 502-508
[39]
R Kessler, M Faller, E Weitzenblum, A Chaouat, A Aykut, A Ducolone, et al.
Natural history of pulmonary hypertension in a series of 131 patients with chronic obstructive lung disease.
Am J Respir Crit Care Dis, 164 (2001), pp. 219-224
[40]
V Balasubramaniam, DD Ivy, TR Grover, JP Kinsella, SH Abman.
Role of platelet derived growth factor in vascular remodeling during pulmonary hypertension in the ovine fetus.
Am J Physiol Lung Cell Mol. Physiol, 284 (2003), pp. L826-L833
[41]
RT Schermuly, E Dony, HA Ghofrani, S Pullamsetti, R Savai, M Roth, et al.
Reversal of experimental pulmonary hypertension by PDGF inhibition.
J Clin Invest, 115 (2005), pp. 2811-2821
[42]
HA Ghofrani, W Seeger, F Grimminger.
Imatinib for the treatment of pulmonary arterial hypertension.
N Engl J Med, 353 (2005), pp. 1412-1413
[43]
SL Merklinger, PL Jones, EC Martínez, M Rabinovitch.
Epidermal growth factor receptor blockade mediates smooth muscle cell apoptosis and improves survival in rats with pulmonary hypertension.
Circulation, 112 (2005), pp. 423-431
[44]
A Fijalkowska, M Kurcyna, A Torbicki, G Szewczyk, M Florczyk, P Pruszczyk, et al.
Serum N-terminal brain natriuretic peptide as a prognostic parameter in patients with pulmonary hypertension.
Chest, 129 (2006), pp. 1313-1321
Copyright © 2007. Sociedad Española de Neumología y Cirugía Torácica (SEPAR)
